Therapeutic approaches in metastatic renal cell carcinoma

被引：15
作者：
Staehler, M [1 ]
Rohrmann, K [1 ]
Bachmann, A [1 ]
Zaak, D [1 ]
Stief, CG [1 ]
Siebels, M [1 ]
机构：
[1] Univ Munich, Klinikum Grosshadern, Urol Klin & Poliklin, Dept Urol, D-81377 Munich, Germany
来源：
BJU INTERNATIONAL | 2005年 / 95卷 / 08期
关键词：
cancer; renal cell cancer; kidney; metastases; therapy;
D O I：
10.1111/j.1464-410X.2005.05537.x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1153 / 1161
页数：9
相关论文
共 146 条
[1]   Hepatic resection for metastatic renal tumors: Is it worthwhile? [J].
Alves, A ;
Adam, R ;
Majno, P ;
Delvart, V ;
Azoulay, D ;
Castaing, D ;
Bismuth, H .
ANNALS OF SURGICAL ONCOLOGY, 2003, 10 (06) :705-710
[2]   Thalidomide therapy for renal cell carcinoma [J].
Amato, RJ .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 46 :S59-S65
[3]  
Amato RJ, 2000, SEMIN ONCOL, V27, P177
[4]   Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial [J].
Andrews, DW ;
Scott, CB ;
Sperduto, PW ;
Flanders, AE ;
Gaspar, LE ;
Schell, MC ;
Werner-Wasik, M ;
Demas, W ;
Ryu, J ;
Bahary, JP ;
Souhami, L ;
Rotman, M ;
Mehta, MP ;
Curran, WJ .
LANCET, 2004, 363 (9422) :1665-1672
[5]   IL-2 in combination with IFN-α and 5-FU versus tamoxifen in metastatic renal cell carcinoma:: long-term results of a controlled randomized clinical trial [J].
Atzpodien, J ;
Kirchner, H ;
Illiger, HJ ;
Metzner, B ;
Ukena, D ;
Schott, H ;
Funke, PJ ;
Gramatzki, M ;
von Jürgensom, S ;
Wandert, T ;
Patzelt, T ;
Reitz, M .
BRITISH JOURNAL OF CANCER, 2001, 85 (08) :1130-1136
[6]   TREATMENT OF METASTATIC RENAL-CELL CANCER-PATIENTS WITH RECOMBINANT SUBCUTANEOUS HUMAN INTERLEUKIN-2 AND INTERFERON-ALPHA [J].
ATZPODIEN, J ;
KORFER, A ;
PALMER, PA ;
FRANKS, CR ;
POLIWODA, H ;
KIRCHNER, H .
ANNALS OF ONCOLOGY, 1990, 1 (05) :377-378
[7]   Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma:: A prospectively German cooperative renal randomized trial of the carcinoma chemoimmunotherapy group (DGCIN) [J].
Atzpodien, J ;
Kirchner, H ;
Jonas, U ;
Bergmann, L ;
Schott, H ;
Heynemann, H ;
Fornara, P ;
Loening, SA ;
Roigas, J ;
Müller, SC ;
Bodenstein, H ;
Pomer, S ;
Metzner, B ;
Rebmann, U ;
Oberneder, R ;
Siebels, M ;
Wandert, T ;
Puchberger, T ;
Reitz, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1188-1194
[8]   SURGICAL-TREATMENT OF BRAIN METASTASES FROM RENAL-CELL CARCINOMA [J].
BADALAMENT, RA ;
GLUCK, RW ;
WONG, GY ;
GNECCO, C ;
KREUTZER, E ;
HERR, HW ;
FAIR, WR ;
GALICICH, JH .
UROLOGY, 1990, 36 (02) :112-117
[9]  
BARBUTO JA, 2004, CANC IMMUNOL IMMUNOT
[10]   A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma [J].
Bennouna, J ;
Delva, R ;
Gomez, F ;
Lesimple, T ;
Geoffrois, L ;
Linassier, C ;
Chevreau, C ;
Douillard, JY ;
Négrier, S .
ONCOLOGY, 2003, 64 (01) :25-27
12345678910